Ketotifen in childhood allergic disease

Warner, J. O.; Sj, Goldsworthy

doi:10.1111/j.1365-2222.1982.tb03295.x

Cited by 12 publications

(8 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Drugs such as Doxantrazole, Proxicromil, Zaprinast and Lodoxamide have been withdrawn from clinical trial because of problems with toxicity and lack of eflicacy. The only 'mast cell stabilizer' to be marketed is Ketotifen, but this drug is unrelated to SCG both chemically and in its mechanism of action [47], The anti-asthmatic effect ofthis potent antihistamine is small and develops slowly, hardly justifying its use primarily for the treatment of asthma [48], Several possible reasons for our failure to develop new SCGlike drugs may be considered.…”

Section: Sodium Cromoglycate-like Compoundsmentioning

confidence: 99%

Sodium cromoglycate and related drugs

Church¹,

Warner²

1985

Clin Experimental Allergy

Self Cite

View full text Add to dashboard Cite

Section: Sodium Cromoglycate-like Compoundsmentioning

confidence: 99%

Sodium cromoglycate and related drugs

Church¹,

Warner²

1985

Clin Experimental Allergy

Self Cite

View full text Add to dashboard Cite

“…Asthma symptoms occurred mainly during the peak and post-peak pollen period (weeks [19][20][21][22][23] and it can be speculated that the reason for this is that it takes some time before the inflammatory process is established in the bronchial mucosa. The groups were not matched for bronchial hyperreactivity by metacholine challenge test.…”

Section: Discussionmentioning

confidence: 99%

Ketotifen in pollen‐induced asthma: a double blind placebo‐controlled study

Broberger

Graff‐Lonnevig

Lilja

et al. 1986

Clin Experimental Allergy

View full text Add to dashboard Cite

Twenty-nine children with an average age of 105 years were studied with respect to the protective effect of ketotifen on pollen-induced bronchial asthma. All of them were sensitive to deciduous tree pollen, the diagnosis being verified by bronchial challenge. The children were stratified in matched pairs and randomly allocated to two treatment groups, placebo or ketotifen 1 mg twice daily. The study was double-blind and was performed during the whole of the deciduous tree pollen season. Daily pollen counts were made, allergic symptoms were noted, additional medication was given and the expiratory pulmonary flow was recorded. During the birch pollen peak the ketotifen group showed significantly fewer, and less severe asthma and rhinoconjunctivitis than the placebo group. The anti-asthmatic medication was also used significantly less than in the placebo group. Ketotifen appeared to have good protective properties in the treatment of pollen-induced asthma and rhinoconjunctivitis.

show abstract

“…Ketotifen, a benzocycloheptathiophene compound, has been used in the treatment of bronchial asthma in Europe and Asia for a long time as a controller [33][34][35]. Its use was superseded by more potent newer inhaled corticosteroids (budesonide and fluticasone) and antileukotriene compounds (montelukast and zafirlukast).…”

Section: Ketotifenmentioning

confidence: 99%